Remus Pharmaceuticals Limited — Board Meeting, 20-06-2025: Outcome of Board Meeting

Remus Pharmaceuticals has announced a board meeting approving the incorporation of a new subsidiary, Espee Global Clinical Trial Services Pvt Ltd. This subsidiary will focus on clinical trial material management and related services, aiming to tap into the growing demand for reliable clinical trial support in India and globally. Remus will hold 68% equity by subscribing ₹6.8 lakh in cash out of the total authorized share capital of ₹10 lakh. This move aligns with Remus’s strategic expansion into clinical trial services alongside its core pharma operations.